Evaluating the addition of metformin and turmeric for prostate cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the feasibility of incorporating a nutritional intervention of metformin and turmeric alongside intermittent Androgen Deprivation Therapy (iADT) for patients with biochemically progressive castration sensitive prostate cancer. Participants will receive both the standard treatment and the nutritional supplements while documenting their intake and completing quality of life questionnaires. Blood and stool samples will be collected to analyze biomarkers and microbiome profiles, contributing to a better understanding of the treatment's impact. The long-term goal is to evaluate the efficacy and safety of this regimen in managing prostate cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older.
* History of prior prostatectomy and/or radiation therapy to the prostate.
* Currently have rising PSA levels ≥ 0.2 ng/ml if they have undergone radical prostatectomy, or a PSA ≥ nadir + 2 if they have received only radiotherapy. Patients who were not offered salvage radiotherapy as an alternative treatment will be considered ineligible (due to a high PSA, other medical concerns).
* Currently have at least 2 consecutively rising serum PSA levels more than 1 week apart
* Currently have a PSA doubling time \< 9 months obtained within 60 days of consent.
* Eugonad with testosterone \> 150 ng/dl at time of consent.
* Prior ADT (including iADT) for up to 24 months in association with definitive treatment is permitted if completed at least 12 months prior to consent.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
* Willing to take study agents at the dose specified with meals.
* Willing to discontinue current vitamin/mineral supplements and use only those provided by study. Herbal supplements may still be used.

Exclusion Criteria:

* Current Chronic Lymphocytic Leukemia (CLL), Monoclonal Gammopathy of Unknown Significance (MGUS), Renal Cell Carcinoma (RCC) or another cancer requiring active treatment. Indolent or stable malignancies such as non-melanoma skin cancers are allowed.
* Any active or deteriorating liver or renal disease, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C or bone marrow deficiency.
* Any history of allergic reactions attributed to turmeric, metformin, or other compounds of similar chemical or biologic compositions.
* History of lactic acidosis or risk factors for lactic acidosis (e.g., renal impairment, concomitant use of carbonic anhydrase inhibitors such as topiramate, hypoxic states such as acute congestive heart failure, excessive alcohol intake, and hepatic impairment).
* Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.

Where it's running

• University of Arkansas for Medical Sciences
  Little Rock, Arkansas, United States Recruiting

Study contacts

• Principal investigator: Shi-Ming Tu, MD — University of Arkansas
• Study coordinator: Emily Baker
• Email: ebaker2@uams.edu
• Phone: 5016868274

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Recurrence-directed therapy with or without 12 months of androgen-deprivation (ELIGARD) for radio-recurrent oligo-metastatic, hormone-sensitive prostate cancer

  This will test whether adding 12 months of ELIGARD® (androgen-deprivation therapy) to recurrence-directed radiotherapy helps men with radio-recurrent oligo-metastatic, hormone-sensitive prostate cancer stay progression-free longer.

  Recruiting at 4 sites Phase 2 Ontario Clinical Oncology Group (OCOG) · Hamilton, Ontario and 4 other locations · NCT06654336

• Evaluating PSMA Changes in Prostate Cancer After Hormonal Therapy

  This study is testing how hormonal therapy changes a specific protein in men with prostate cancer to see if those changes can help doctors understand the cancer better.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT05919329

• Testing a new injection for men with advanced prostate cancer

  This study is testing a new injection for men with advanced prostate cancer to see how well it works and how safe it is.

  Recruiting at 15 sites Phase 1 Astellas Pharma Inc · Tucson, Arizona and 24 other locations · NCT04729114

• Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve

  This trial will test whether adding the investigational drug mevrometostat to enzalutamide helps men with metastatic castration‑sensitive prostate cancer who have not received androgen receptor pathway inhibitors or chemotherapy.

  Recruiting at 145 sites Phase 3 Pfizer · Huntsville, Alabama and 318 other locations · NCT07028853

• Adding docetaxel to hormonal therapy and apalutamide for metastatic prostate cancer

  This trial tests whether giving the chemotherapy drug docetaxel in addition to hormone therapy and apalutamide helps men with metastatic castration-sensitive prostate cancer live longer.

  Recruiting at 208 sites Phase 3 Alliance for Clinical Trials in Oncology · Tucson, Arizona and 213 other locations · NCT06931340

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.